Chemist + Druggist is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Omnicell launches software to manage medication stock

Manufacturer Omnicell has launched a new software for medication inventory management.

The MedX software – which Omnicell unveiled at the Clinical Pharmacy Congress held at the ExCeL centre in London last week (September 23-24) – provides one clear view of pharmacy inventory in real time.

Clinicians can access real-time dashboards direct from their mobile phone, the manufacturer said.

The solution makes it easier to track medicines in the event of a product recall and frees up clinicians’ time from searching overburdened shelves and managing stock levels, allowing them to spend more time with patients, Omnicell added.

Commenting on the launch of the product, Omnicell UK&I automation director Edward Platt said the “technology can really bring valuable insights to healthcare partners’ clinical workflows and medication management processes”.

The price of the software is “bespoke to the solution provided”, the manufacturer added.

For more information, visit the Omnicell website or email [email protected]

Related Content


Pharmacist Managers - Recruiting Now !
East London, Essex and Luton
£40,000 - £50,000 per year

Apply Now



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts